Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

Amplia has announced that recruitment of the final cohort of patients in the ACCENT clinical trial has begun with the first patient having started on trial this week.

A total of 50 patients are planned for the Phase 2a ACCENT trial. Recruitment of this final cohort of 24 patients is open at the existing trial sites in Australia and South Korea, including the Calvary Mater Hospital in Newcastle that became an active trial site this week. Recruitment is expected to be completed by end of Q1 2025.

Amplia CEO and MD Dr Chris Burns commented:

“We are very pleased to begin recruitment of the remaining 24 patients for the ACCENT trial. We plan to complete recruitment by the end of March 2025, and to increase the opportunities for patients to join the trial we have this week also opened recruitment at the Calvary Mater Hospital in Newcastle."

Click link below to read the full ASX Release.

Recruitment Restarts in Accent Pancreatic Cancer Trial